{"preliminary_commentary":{"by_channel":{"x_thread":8},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04547504\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"PERSEE","nct_id":"NCT04547504","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=persee-nct04547504. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PERSEE","arms":[{"description":"Pembrolizumab","label":"Pembrolizumab","type":"ACTIVE_COMPARATOR"},{"description":"Chemotherapy and Pembrolizumab","label":"Chemotherapy-Pembrolizumab","type":"ACTIVE_COMPARATOR"}],"collaborators":["Groupe Francais De Pneumo-Cancerologie"],"completion_date":{"date":"2025-12-22","type":"ESTIMATED"},"conditions":["Non-small-cell Lung Cancer"],"enrollment":{"count":349,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab and Chemotherapy drugs","otherNames":[],"type":"DRUG"}],"last_update":"2025-09-17","lead_sponsor":"University Hospital, Brest","official_title":"Randomized, Open-label, Controlled Phase III Trial Comparing Pembrolizumab-platinum Based Chemotherapy Combination With Pembrolizumab Monotherapy in First Line Treatment of Non-small-cell Lung Cancers (NSCLC) With PDL1 Expression ≥50%","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-12-22","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) according to RECIST 1.1 assessed by blinded inependant centra review (BICR)","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months"}],"references":[{"citation":"Descourt R, Chouaid C, Perol M, Besse B, Greillier L, Bylicki O, Ricordel C, Guisier F, Gervais R, Schott R, Auliac JB, Robinet G, Decroisette C. First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression >/=50. Future Oncol. 2021 Aug;17(23):3007-3016. doi: 10.2217/fon-2020-1202. Epub 2021 Jun 22.","pmid":"34156285","type":"DERIVED"}],"start_date":{"date":"2020-12-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %","url":"https://clinicaltrials.gov/study/NCT04547504"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/persee-nct04547504"}